All the news Showing 10 of 67 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Hepatitis B patients on long-term entecavir or tenofovir have low mortality, but liver cancer remains a risk Liz Highleyman / 03 June 2015 More than 95% of people with chronic hepatitis B were still alive after five years on antiviral therapy with entecavir (Baraclude) or tenofovir (Viread) and most deaths were due to non-liver-related causes, according ... Stopping tenofovir is safe for people with hepatitis B on long-term therapy Liz Highleyman / 02 June 2015 Most people with hepatitis B virus (HBV) who stopped taking tenofovir (Viread) after more than three years on treatment had good outcomes, according to a presentation at the recent European Association for the ... Nucleic acid polymer REP 2139-Ca shows promising activity against hepatitis B and hepatitis delta Liz Highleyman / 15 May 2015 The nucleic acid-based polymer REP 2139-Ca lowered hepatitis B surface antigen (HBsAg) levels and significantly reduced hepatitis B and hepatitis delta viral loads when combined with immunotherapy, according to presentations at the European ... Expanded vaccination and treatment could help eliminate hepatitis B worldwide Liz Highleyman / 28 April 2015 While universal infant hepatitis B virus (HBV) vaccination has already led to major advances in reducing new infections in some settings, further expansion of prevention and treatment are needed to significantly reduce HBV ... Global hepatitis B epidemic treatable at cost of just $36 per patient per year Michael Carter / 08 April 2015 Large-scale production of generic entecavir could cut the cost of first-line hepatitis B virus (HBV) therapy to just US$36 per patient per year, according to a study published in the online version of ... Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients Liz Highleyman / 05 February 2015 People with chronic hepatitis B virus (HBV) infection are more likely to experience favourable treatment response, as indicated by hepatitis B surface antigen (HBsAg) loss, if they add pegylated interferon to tenofovir – ... Entecavir and tenofovir work well for people with drug-resistant hepatitis B virus Liz Highleyman / 04 February 2015 A combination of entecavir plus tenofovir effectively suppressed hepatitis B virus (HBV) in people with resistance to other antivirals, according to results from the European ENTEBE study presented at the American Association for ... Tenofovir continues to suppress hepatitis B virus for eight years Keith Alcorn / 05 December 2014 Most people with chronic hepatitis B who are treated with tenofovir for eight years continued to maintain viral suppression, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver ... Adding interferon to nucleoside antivirals may improve response for people with chronic hepatitis B Liz Highleyman / 24 April 2014 Adding pegylated interferon to entecavir (Baraclude) led to greater hepatitis B virus (HBV) viral load decline and higher likelihood of serological response in people with HBeAg-positive chronic hepatitis B, as did added interferon after ... Prolonged pegylated interferon plus tenofovir does not prevent hepatitis delta relapse Liz Highleyman / 23 April 2014 Treating hepatitis B patients with hepatitis delta virus (HDV) co-infection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side-effects are frequent and it did not significantly improve ... ← Prev1...34567Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive